<DOC>
	<DOCNO>NCT00805675</DOCNO>
	<brief_summary>The purpose study compare safety , tolerability effectiveness 12 week treatment telbivudine 600 mg daily plus tenofovir DF 300 mg one daily ( OD ) take together vs. tenofovir DF 300 mg daily ( QD ) vs telbivudine 600 mg monotherapy daily ( QD ) . This open label , active control , viral kinetics study mean subject study doctor know study drug subject assign . This study open male female subject , &lt; 40 year age , infect HBV least 6 month receive oral treatment HBV .</brief_summary>
	<brief_title>Effects Telbivudine Tenofovir Disoproxil Fumarate Treatment Hepatitis B Virus DNA Kinetics CHB</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Chronic HBV infection , define positive serum HBsAg least 6 month , HBsAg positive &gt; 3 month negative IgM antiHBc positive IgG antiHBc Age &lt; 40 year old HBeAg positive HBV DNA &gt; = 10^7 copies/mL Abbott realtime PCR ALT &lt; = 1 ULN Willing able provide write informed consent No prior oral HBV therapy ( e.g. , nucleotide and/or nucleoside therapy investigational agent HBV infection ) Is willing able comply study drug regimen study procedure requirement Is willing able provide write informed consent study assessment perform Decompensated liver disease define direct ( conjugate ) bilirubin &gt; 1.2 × ULN , PT &gt; 1.2 × ULN , platelets &lt; 150,000/mm3 , serum albumin &lt; 3.5 g/dL , prior history clinical hepatic decompensation ( e.g . ascites , jaundice , encephalopathy , variceal hemorrhage ) . Received interferon ( pegylated ) therapy within 6 month screen visit αfetoprotein &gt; 50 ng/mL Evidence hepatocellular carcinoma ( HCC ) Coinfection HCV ( serology ) , HIV , Significant renal , cardiovascular , pulmonary , neurological disease . Received solid organ bone marrow transplantation . Is currently receive therapy immunomodulators ( e.g. , corticosteroid , etc . ) , investigational agent , nephrotoxic agent , agent susceptible modify renal excretion . Has proximal tubulopathy . Use investigational drug time enrollment , within 30 day History hypersensitivity study drug drug similar chemical class Is pregnant breastfeeding . Is woman childbearing potential ( WOCBP ) unless postmenopausal use one acceptable method contraception . Patient concurrent medical social condition likely preclude compliance schedule evaluation protocol , likely confound efficacy safety observation study . Patient currently abuse alcohol illicit drug , history alcohol abuse illicit substance abuse within precede two year . Patient medical condition require prolonged frequent use systemic acyclovir famciclovir . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Chronic HBV</keyword>
	<keyword>Asian adult subject chronic HBV , immune tolerant phase , positive hepatitis B e antigen ( HBeAg )</keyword>
</DOC>